Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease

Table 3 Univariate analysis of clinical factors influencing the efficacy

	MOX-ST		CLA-ST
	Eradication rate	P value	Eradication rate	P value
Age (yr)		0.436		0.002
< 60	97.2% (35/36)		81.1% (30/37)
≥ 60	90.4% (38/42)		70.0% (28/40)
Gender		0.383		0.622
Male	91.1% (31/34)		71.8% (23/32)
Female	95.4% (42/44)		77.7% (35/45)
Body mass index		0.651		0.743
< 25	95.2% (20/21)		86.9% (20/23)
≥ 25	92.9% (53/57)		70.3% (38/54)
Smoking		0.585		0.377
(-)	97.0% (65/67)		77.6% (52/67)
(+)	72.7% (8/11)		60.0% (6/10)
Alcohol		0.417		0.082
(-)	96.9% (63/65)		77.9% (53/68)
(+)	76.9% (10/13)		55.5% (5/9)
Diabetes		0.706		0.107
(-)	94.5% (70/74)		76.8% (53/69)
(+)	75.0% (3/4)		62.5% (5/8)
Hypertension		0.322		0.096
(-)	91.6% (55/60)		79.6% (43/54)
(+)	100.0% (18/18)		65.2% (15/23)
History of ulcer		0.454		0.828
(-)	92.5% (62/67)		75.0% (51/68)
(+)	100.0% (11/11)		77.7% (7/9)
Presence of ulcer		0.352		0.076
(-)	92.6% (63/68)		78.7% (52/66)
(+)	100.0% (10/10)		54.5% (6/11)
Positive CLOtest		0.259		0.374
(-)	76.1% (16/21)		63.1% (12/19)
(+)	100.0% (57/57)		79.3% (46/58)
Atrophic change		0.111		0.071
(-)	95.7% (67/70)		76.0% (57/75)
(+)	75.0% (6/8)		50.0% (1/2)
Intestinal metaplasia		0.270		0.322
(-)	95.5% (65/68)		76.5% (49/64)
(+)	80.0% (8/10)		69.2% (9/13)
Bacterial density		0.296		0.507
None	66.7% (2/3)		60.0% (3/5)
Mild	90.6% (29/32)		67.6% (23/34)
Moderate	100.0% (32/32)		78.2% (18/23)
Marked	90.9% (10/11)		93.3% (14/15)
Compliance		NS		NS
Poor	0.0% (0/0)		0.0% (0/0)
Good	93.6% (73/78)		75.3% (58/77)
Adverse events		0.493		0.494
(-)	92.6% (63/68)		77.6% (45/58)
(+)	100.0% (10/10)		68.4% (13/19)

MOX-ST: 14-d moxifloxacin-based sequential therapy; CLA-ST: 14-d clarithromycin-based sequential therapy; CLOtest: Rapid urease test; NS: Not significant.